Intrapartum Management in Maternal Brugada Syndrome Authors: Helena Y. Hong, Gina F. Milone, Jaber J. Hanhan, Brittany File, Afshan B. Hameed Published: 2023 ABSTRACT Brugada syndrome is a genetic cardiac disease associated with increased risk of ventricular tachyarrhythmia and sudden cardiac arrest. Labor and delivery in this population poses management challenges of labor induction, analgesia, postpartum hemorrhage, and arrhythmic events. This case report describes a multidisciplinary approach to intrapartum management in maternal Brugada syndrome. History of presentation A 19-year-old G1P0 with Brugada syndrome presented to our university maternal-fetal medicine (MFM) office for transfer of care at 37 weeks 2 days gestation. Significant family history of early sudden cardiac death included both her father, who experienced cardiac arrest around 40 years of age while driving, and her sister, deceased at 24 years of age while sleeping. Her father was diagnosed with Brugada syndrome following his accident, with genetic testing confirming SCN5A c.4172G>T (p.Gly1391Val) mutation, a variant of unknown significance (VUS). The patient herself never had any life-threatening arrhythmias. She was diagnosed with Brugada syndrome 1.5 years before pregnancy after presenting with fever due to infection and had a characteristic type I Brugada electrocardiogram (ECG) pattern (Figure 1). She declined implantable cardioverter-defibrillator (ICD) placement prior to pregnancy.Learning Objectives•To be able to recognize triggers for ventricular arrhythmia in Brugada syndrome.•To understand the interaction between these triggers and the needs of labor and delivery.•To implement a plan of care to minimize risk in intrapartum management of maternal Brugada syndrome.Figure 1Type I Brugada PatternThe patient’s electrocardiogram showing characteristic type I Brugada pattern with coved ST-segments >2 mm in leads V1 and V2. Learning Objectives •To be able to recognize triggers for ventricular arrhythmia in Brugada syndrome.•To understand the interaction between these triggers and the needs of labor and delivery.•To implement a plan of care to minimize risk in intrapartum management of maternal Brugada syndrome. •To be able to recognize triggers for ventricular arrhythmia in Brugada syndrome. To be able to recognize triggers for ventricular arrhythmia in Brugada syndrome. •To understand the interaction between these triggers and the needs of labor and delivery. To understand the interaction between these triggers and the needs of labor and delivery. •To implement a plan of care to minimize risk in intrapartum management of maternal Brugada syndrome. To implement a plan of care to minimize risk in intrapartum management of maternal Brugada syndrome. Type I Brugada Pattern The patient’s electrocardiogram showing characteristic type I Brugada pattern with coved ST-segments >2 mm in leads V1 and V2. The patient’s baseline ECG showed a type II Brugada pattern. Echocardiogram showed a structurally and functionally normal heart with an ejection fraction of 61%. Given her term gestation on presentation, she was sent to labor and delivery (L&D) for expedited delivery planning. Management A multidisciplinary meeting was held between the MFM, anesthesia, and cardiology teams. Recommendations were made regarding induction of labor, analgesia, and cardiac considerations. Certain commonly used pharmacologic agents were identified as absolutely or relatively contraindicated. The patient was offered a primary cesarean section or induction of labor and desired to proceed with induction. In preparation for labor, she was placed on continuous telemetry with defibrillator pads applied. Isoproterenol was available in the room. In the event of cardiac arrest without return of spontaneous circulation after 4 minutes, an emergent bedside cesarean delivery would be performed. Initial cervical exam showed she was 1 cm dilated. A cervical ripening balloon and misoprostol were used to minimize prolonged oxytocin exposure. When the balloon fell out after 12 hours, exam showed she was 5 cm dilated. Low-dose oxytocin was started and augmented with artificial rupture of membranes (AROM). The first stage of labor progressed appropriately with a maximum oxytocin dose of 6 mU/min. Four doses of intravenous morphine 4 mg were given for pain. Combined spinal-epidural was placed per patient request at 8 cm dilation with a spinal dose of fentanyl 5 μg, bupivacaine 2.5 mg (2.5 mL of bupivacaine 1%), and morphine 100 μg. Shortly after, she was 10 cm dilated. She labored down for 2 hours to minimize Valsalva and then pushed to +2 station without subsequent descent. She required additional anesthesia before attempting operative vaginal delivery, and a pudendal block was administered with 20 mL 1% lidocaine. Vacuum-assisted vaginal delivery was attempted but unsuccessful with minimal fetal descent. Delivery was therefore converted to a primary cesarean section under general anesthesia to avoid surgical loading doses of regional anesthesia. With placental delivery, prophylactic intramuscular oxytocin and intravenous tranexamic acid were administered. Despite this, the patient experienced uterine atony and postpartum hemorrhage. Methylergonovine, a contraindicated medication, was avoided. Postpartum hemorrhage was managed medically with additional intramuscular carboprost 250 μg ×2, a second dose of intravenous tranexamic acid 1 g, a second dose of intramuscular oxytocin 15 U, buccal misoprostol 800 μg, and surgically with O’Leary stitches. Quantitative blood loss was 1,155 mL. Intraoperative telemetry revealed conversion to a type I Brugada ECG pattern. Postpartum, the patient was admitted to the cardiac intensive care unit (ICU) for monitoring given the type I Brugada pattern. She did not experience any cardiac events and was downgraded to L&D on postoperative day 1. Mother and baby were discharged on postoperative day 2. Genetic testing during her admission revealed the patient carries the same mutation as her father, SCN5A c.4172G>T (p.Gly1391Val) (VUS). The patient gave written consent to have her case published. Discussion Brugada syndrome is a rare electrophysiologic cardiac disorder that increases the risk of ventricular tachyarrhythmias, syncopal episodes, and sudden cardiac death.1 Brugada syndrome is responsible for up to 20% of all sudden cardiac deaths in patients with structurally normal hearts, and sudden cardiac death is the presenting manifestation in approximately 30% of patients with Brugada syndrome.2 It is defined by characteristic ECG findings of marked ST-segment elevation in the right precordial leads (V1-V3). Brugada syndrome follows autosomal dominant inheritance with variable penetrance. After appraisal of more than 20 genes, only a mutation in SCN5A, a gene encoding cardiac sodium channels, was found to have definitive causal evidence.3 This mutation has been identified in up to 25% of patients with Brugada syndrome, with a female predominance, with carriers having a higher risk of major cardiac events at younger ages (on average, at 34 years of age compared to 42 years of age).4,5 A minority of Brugada syndrome patients are female (23%).6 However, these women tend to have a higher rate of family history of sudden cardiac death, a higher rate of concealed ECG pattern on presentation, and, again, a higher rate of genetic mutation.4,6 Delivery of these patients should occur in a hospital where MFM, cardiology, and obstetric anesthesia are available. Existing literature (Supplemental Table 1) on Brugada syndrome in pregnancy focuses on the anesthetic considerations given many contraindicated medications. We aim to focus on the obstetric considerations given the limited literature by comparison. Table 1 summarizes peripartum recommendations, which are further discussed below. These recommendations are based on indirect evidence and expert opinion rather than empiric studies.Table 1Recommendations for Peripartum Management in Maternal Brugada SyndromeStageRecommendationContingency planning during laborContinuous telemetryDefibrillator pads on patientIsoproterenol at bedside in the event of cardiac arrhythmiaPerimortem cesarean section if indicated, with equipment at bedsideInduction/augmentation of laborMembrane sweep before balloon placementCervical ripening balloon with misoprostolDelay Pitocin until cervix is favorable, attempt to avoid higher doses (>10 mU/min)Delay AROM if feasibleLabor analgesiaAdminister intravenous and intramuscular morphine in latent laborDelay neuraxial anesthesia until active labor if possible to minimize exposure to local anestheticInitiate combined spinal-epidural Administer spinal first with morphine (Duramorph) to prolong spinal analgesia.a Do not start epidural infusion yet. When spinal has worn off, activate epidural with test dose and administer intermittent boluses of lidocaine.bSecond stage of labor and vaginal deliveryMinimize Valsava Labor down, assuming clinical status allows Consider operative vaginal delivery to decrease Valsava durationAnesthesia conversion for cesareanAvoid loading epidural catheterRapid sequence intubation with propofol and succinylcholine or rocuronium Allow propofol for induction; avoid propofol for infusionReverse paralysis with sugammadexPostpartum hemorrhageProphylactic tranexamic acid with placenta deliveryAvoid methylergonovineCarboprost as first-line uterotonic; re-dose every 15 min for maximum of 5 dosesPostpartum monitoringConsider admission to cardiac ICU if patient is at high risk for arrhythmiaContinuous telemetry for at least 24 h postpartumAROM = artificial rupture of membranes; ICU = intensive care unit.aSpinal medications: fentanyl 5 μg, bupivacaine 2.5 mg (2.5 mL of bupivacaine 0.1%), morphine (Duramorph) 100 μg.bIntermittent boluses of maximum 10 mL of 1% licocaine at a time. Table 1Recommendations for Peripartum Management in Maternal Brugada SyndromeStageRecommendationContingency planning during laborContinuous telemetryDefibrillator pads on patientIsoproterenol at bedside in the event of cardiac arrhythmiaPerimortem cesarean section if indicated, with equipment at bedsideInduction/augmentation of laborMembrane sweep before balloon placementCervical ripening balloon with misoprostolDelay Pitocin until cervix is favorable, attempt to avoid higher doses (>10 mU/min)Delay AROM if feasibleLabor analgesiaAdminister intravenous and intramuscular morphine in latent laborDelay neuraxial anesthesia until active labor if possible to minimize exposure to local anestheticInitiate combined spinal-epidural Administer spinal first with morphine (Duramorph) to prolong spinal analgesia.a Do not start epidural infusion yet. When spinal has worn off, activate epidural with test dose and administer intermittent boluses of lidocaine.bSecond stage of labor and vaginal deliveryMinimize Valsava Labor down, assuming clinical status allows Consider operative vaginal delivery to decrease Valsava durationAnesthesia conversion for cesareanAvoid loading epidural catheterRapid sequence intubation with propofol and succinylcholine or rocuronium Allow propofol for induction; avoid propofol for infusionReverse paralysis with sugammadexPostpartum hemorrhageProphylactic tranexamic acid with placenta deliveryAvoid methylergonovineCarboprost as first-line uterotonic; re-dose every 15 min for maximum of 5 dosesPostpartum monitoringConsider admission to cardiac ICU if patient is at high risk for arrhythmiaContinuous telemetry for at least 24 h postpartumAROM = artificial rupture of membranes; ICU = intensive care unit.aSpinal medications: fentanyl 5 μg, bupivacaine 2.5 mg (2.5 mL of bupivacaine 0.1%), morphine (Duramorph) 100 μg.bIntermittent boluses of maximum 10 mL of 1% licocaine at a time. Recommendations for Peripartum Management in Maternal Brugada Syndrome AROM = artificial rupture of membranes; ICU = intensive care unit. Spinal medications: fentanyl 5 μg, bupivacaine 2.5 mg (2.5 mL of bupivacaine 0.1%), morphine (Duramorph) 100 μg. Intermittent boluses of maximum 10 mL of 1% licocaine at a time. Management focuses on minimizing factors that provoke ventricular arrhythmias and sudden cardiac death. Although pregnancy-related arrhythmias are rare, the high number of potential triggers necessitates caution.7,8 A list of medications to avoid or use with caution has been curated by BrugadaDrugs.org.9 Key contraindicated medications include methylergonovine, and anesthetics such as bupivacaine and propofol. Class 1C anti-arrhythmics such as flecainide and propafenone are contraindicated, whereas isoproterenol and quinidine are preferred.10 There are no known absolute contraindications to mechanical or pharmacologic labor induction agents. Theoretically, oxytocin increases arrhythmia risk due to its mechanism of action of triggering intracellular calcium release. Therefore, we developed a low-dose oxytocin induction protocol with maximum dose of 10 mU/min. Immediately following delivery, we routinely administer prophylactic intravenous oxytocin at rapid infusion rates of 30 U/h for 1 hour, followed by a second bag at 7.5 U/h for 4 hours, for a total of 60 U oxytocin. In this case, we opted for intramuscular oxytocin 15 U, followed by a second dose of intramuscular oxytocin 15 U 1 hour later. In total, the patient received 12 U of oxytocin in labor and 30 U postpartum. Fever is a major precipitant of arrhythmia. Although labor induction should not be obstructed, early AROM should be avoided if possible to minimize infection risk with prolonged rupture. If intra-amniotic infection develops, cesarean delivery should remain reserved for usual obstetric indications and should be managed aggressively with antipyretics, cooling measures, and antibiotics. The cause of intraoperative conversion to a type I Brugada pattern on the patient’s telemetry is unclear, although it is suspected to be the accumulation of pro-arrhythmic factors such as Valsalva during the second stage of labor, local anesthetics from combined spinal-epidural and pudendal nerve block, and the autonomic changes in response to intra-abdominal surgery. In general, the risk of arrhythmia in pregnancy is highest during the postpartum period. Following placental delivery, up to 500 mL of blood previously delivered to the uterus is “autotransfused” into maternal circulation. This increases cardiac output by 30% to 50%, predisposing patients to arrhythmia. Postpartum telemetry is advised in high-risk populations such as those with Brugada syndrome. Follow-up Upon hospital discharge, outpatient follow-up with cardiology, obstetrics/gynecology, and genetics is critical for evaluation of implantable cardioverter-defibrillator placement, recommendation for reliable contraception, and genetic testing of family members, including the newborn. Conclusions This case challenged a multidisciplinary team to create and implement a set of practices for safe labor and delivery in a patient with Brugada syndrome. Funding Source and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.